explore
WASHINGTON — UCB left BIO at the end of 2023, the second major member company to exit after Pfizer pulled out as well.
UCB, headquartered in Belgium, decided not to renew its BIO membership after a routine evaluation of its engagement in trade associations, said company spokesperson Erica Puntel.
advertisement
NewslettersSign up for D.C. Diagnosis
Washington never stops. Cut through the noise with our essential updates on health care politics and policy
Please enter a valid email address. Privacy PolicyPfizer, whose departure STAT reported first, was listed on BIO’s website as a sponsor at one of the group’s highest levels. Pfizer bought Global Blood Therapeutics, which current BIO Board Chair Ted Love led to the approval of a drug to treat sickle cell disease, in 2022.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log InNext article： Medicare details structure of new drug price negotiation program
